The "cell of origin" of the second most common lung cancer and the way that it becomes dominant in the lung have been ...

Generally speaking, you'll find cell phone deals coming in two forms - first as an outright sale on an unlocked device, and secondly as part of a carrier-plan tie-in. The latter can be a bit ...

In healthy cells, cyclin D1 is expressed during the G1 phase of the cell cycle, where it activates CDK4 and CDK6. Its dysregulation is a well-established oncogenic driver in numerous human cancers.

Objectives: This study aimed to evaluate the effectiveness of deep learning model in assisting dermatologists in classifying basal cell carcinoma (BCC) from seborrheic keratosis (SK). The goal was to ...

Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to ...

“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...

This paper investigates how isoform II of transcription factor RUNX2 promotes cell survival and proliferation in oral squamous cell carcinoma cell lines. The authors used gain and loss of function ...

The basal state co-expresses both epithelial and mesenchymal programs and has a distinct epigenetic landscape with accessible chromatin across gene sets that mark cancer cell states with divergent ...

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using ...

researchers delivered 7.7 to 22.3 times more of the drug inside cancer cells, making the treatment up to 23 times more potent than before, according to the study published April 17 in Cell.